/PRNewswire/ Global biotechnology leader CSL (ASX: CSL) today announced that the European Commission has granted conditional marketing authorization (CMA).
Nearly all patients treated with a one-time gene therapy shot for hemophilia B were able to discontinue full-dose bleeding prophylaxis, says a study. Annual bleed rates fell by 64% after the lead-in period.
CSL Reports Positive Final Analysis of Pivotal HOPE-B Study of Gene Therapy in Hemophilia B globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.